Medicare coverage of weight loss drugs could save billions

The latest weight loss drugs, such as GLP-1s like Wegovy and Zepbound, can have a significant impact on treating obesity and related health conditions in the U.S. However, the focus on price controls in political conversations may hinder their accessibility. While concerns about the initial high prices exist, past examples show that competition in the market can drive down costs over time. Implementing price controls, though beneficial in the short term, may stifle innovation and potentially cost lives in the long run. Government intervention in Medicare coverage and promoting private insurance coverage for weight loss drugs could generate substantial social benefits and improve public health outcomes.

Source link

error: Content is protected !!